News

2024/03/28: Announcement regarding the Appointment of New Outside Director

2024/03/22: Presentation at the 23rd Congress of the Japanese Society for Regenerative Medicine Challenge for Manufacturing Gene-modified T cells using an Automated Culture System (updated content 2024/03/27)

2023/12/18: [Delayed]Supplemental Comments on the Termination of the License Agreements for NIB102 and NIB103

2023/12/16: Announcement on the Termination of License Agreement for NIB102 and NIB103

2023/12/06: Our President & CEO, Koji Tamada, made an appearance on Radio NIKKEI “この企業に注目！相場の福の神” on December 1, 2023 (Friday).

2023/12/06: Noile-Immune Biotech's Position on Secondary Tumor Risk in CAR-T Cell Therapy

2023/11/15: Noile-Immune Presents Business Strategy at the Jefferies London Healthcare Conference

2023/11/07: Poster Presentation at the Society for Immunotherapy of Cancer (SITC) Mechanism of Action for the Anti-Tumor Effects of CAR-T Cells Expressing IL-7 and CCL19

2023/10/20: Citeline Pharma Intelligence Awards Japan 2023 Selection of Finalists in Four Categories

2023/10/11: Dr. Tamada, President and CEO, will present a lecture on "Recent Progress and Future Perspectives of CAR-T Cell Therapy against Solid Cancers" at BioJapan 2023, one of the largest partnering events in Asia, on October 12th at Pacifico Yokohama.

2023/09/06: Achievement of Milestone in License Agreement with Chugai Pharmaceutical

2023/08/09: Our President & CEO, Koji Tamada, will make a presentation regarding PRIME technology at the 8th CAR-TCR Summit in Boston.

2023/07/31: Partnership with Sysmex on functional optimization techniques for CAR-T cells

2023/07/03: Koji Tamada, Representative Director & CEO, will give a lecture at "Biopharmaceutical EXPO" (at Tokyo Big Sight) on Friday, July 7, from 12:00 to 13:00.; [Biopharmacetutical EXPO Special Session] BP-S5 Forefront of Next-Generation CAR-T Cell Therapy
Title : Frontiers of Cancer Therapy with CAR-T Cells
Speaker: Koji Tamada, MD, Ph.D.
The seminar information is here.

2023/06/28: Notice of Listing on the Tokyo Stock Exchange Growth Market

2023/05/25: Notice of Approval for Listing on the Tokyo Stock Exchange Growth Market

2023/04/24: Alliance between Noile-Immune Biotech, Inc. and Rebirthel Co., Ltd. on PRIME allogeneic CAR-T Cell Therapy using Immune Cells induced from Pluripotent Stem Cells

2023/04/24: An interview with our president and CEO, Koji Tamada, was published in the International Pharmaceutical Intelligence Magazine (Dec. 26, 2022 published) under the title of "Top Interview: Creating New Therapeutic Options for Solid Cancer with PRIME CAR-T Cell Technologies." (the article is in Japanese)

2023/04/13: Publication of Research Papers on CAR-T Cells with Our Platform-based Technologies

2022/11/25: Interim results of Phase 1 clinical trial evaluating the ‘PRIME' CAR-T cell therapy TAK-102 (NIB102) expressing IL-7/CCL19 in patients with GPC3 positive solid tumors were presented at the 37th Annual Meeting of SITC

2022/09/12: On September 11, 2022, our president, Koji Tamada, appeared on NHK Science Zero, ”Challenge cancer with immune-therapy ! CAR-T Cell Therapy”

2022/08/31: Implementation of a Third-Party Allocation of New Shares

2022/08/22: Chugai and Noile-Immune Biotech Enters into a License Agreement for Noile-Immune’s PRIME CAR-T Technology

2022/06/17: Noile Immune Biotech was introduced as one of Japan's five hottest biotech companies in healthcare at the Labiotech.eu website.
Please refer our website about the details of our pipelines mentioned in the article.

2022/05/18: Adaptimmune Presents at ASGCT with Preclinical Proof-of-Concept Data Supporting Future Clinical Development with a Next-generation SPEAR T-cell using PRIME technology

2022/05/10: Genetic Engineering & Biotechnology News featured Noile-Immune Biotech as one of the companies in Asia being committed to cancer immunotherapy.

2022/02/18: Termination of Collaborative Research and License Agreement with Legend Biotech, Inc.

2021/12/24: Initiation of Phase I Clinical Trial of NIB103/TAK-103

2021/10/25: Noile-Immune Biotech Enters Collaboration with DAIICHI SANKYO COMPANY, LIMITED on Technology Assessment

2021/09/14: Announcement of Clinical Trial Notification (CTN) submission of NIB101 Phase 1 Clinical Trial for Solid Tumors in Japan

2021/03/22: Implementation of Series C Round Fundraising

2020/09/11: Announcement of New President

2020/09/11: Initiation of Phase I Clinical Trial of NIB 102 TAK 102

2020/06/04: Noile-Immune Biotech Enters Collaboration with Chugai Pharmaceutical on Technology Assessment

2020/05/26: C4U and Noile-Immune Biotech Partnership on PRIME Allogeneic CAR-T Cell Therapy Using CRISPR/Cas3 Genome Editing Technology

2020/05/05: Legend Biotech and Noile-Immune Biotech Announce Collaborative Research and Licensing Agreement

2020/03/31: Noile-Immune Biotech Welcomes Pharmaceutical Industry Leader to its Board of Directors

2020/03/31: Appointment of director and International business supervisor

2020/03/31: Strategic partnership via series B financing

2019/11/13: Autolus Therapeutics and Noile-Immune Announce Licensing Agreement

2019/11/06: Noile-Immune Biotech Announces Agreement on a Collaborative Development of an Automated Manufacturing System for Cancer Immunotherapy Cells with Shibuya Corporation

2019/08/27: Adaptimmune and Noile-Immune announces agreement to develop SPEAR T-Cell Products expressing IL-7 and CCL19 as a next-generation treatment for cancer patients

2019/01/03: Noile announces agreement on the license of NIB-102 and NIB-103 with Takeda

2018/11/20: Implemented a third-party allocation of new shares.

2018/05/31: Implemented a third-party allocation of new shares.

2018/03/06: Noile Immune Biotech, Inc. announces that publication Next generation CAR-T cell therapy, "Prime-CAR-T" platform from Yamaguchi University.

2017/09/08: Implemented a third-party allocation of new shares.

2017/09/04: Takeda and Noile-Immune Biotech Collaborate to Advance Next Generation CAR-T Cell Therapy Effective for Solid Tumors.